Barclays analyst Carter Gould initiated coverage of Pfizer with an Equal Weight rating and $36 price target. The analyst initiated coverage of the U.S. Biopharmaceuticals industry with a Positive view citing waning near-term concerns on drug pricing reform, evidence of innovation and attractive valuations. While abrocitinib data is a near-term upside risk to Pfizer shares, the stock is unlikely to break out without additional business development or Ibrance data, says Gould.
Unusual total active option classes on open include: Ekso Bionics (EKSO), 180 Life Sciences (ATNF), DoorDash (DASH), Alibaba (BABA), BP (BP), UP Fintech Holding Ltd (TIGR), Chewy (CHWY), Canopy Growth (CGC), Riot Blockchain (RIOT), and Pfizer (PFE).
Shares of China-based phone maker UTime rose almost 900% above its $4 initial public offering price on Tuesday as the stock opened for trading on the Nasdaq. Meanwhile, Coinbase is... To see the rest of the story go to thefly.com. See Story Here